{"url":"https://nivawealth.com/firms/paradigm-biocapital-advisors-312544","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/312544","regulatoryAum":4469161523,"crd":"312544","history":[{"filedOn":"2021-06-23","regulatoryAum":129324219,"clients":3,"employees":4,"offices":1},{"filedOn":"2022-03-30","regulatoryAum":401348020,"clients":3,"employees":6,"offices":1},{"filedOn":"2023-03-29","regulatoryAum":933207592,"clients":4,"employees":7,"offices":1},{"filedOn":"2024-03-28","regulatoryAum":2358206292,"clients":4,"employees":8,"offices":1},{"filedOn":"2025-03-28","regulatoryAum":3054844396,"clients":4,"employees":9,"offices":1},{"filedOn":"2026-08-27","regulatoryAum":4469161523,"clients":4,"employees":11,"offices":1}],"secFileNumber":"801-120338","legalName":"Paradigm Biocapital Advisors LP","displayName":"Paradigm BioCapital Advisors","slug":"paradigm-biocapital-advisors-312544","website":"https://paradigmbiocapital.com/","logo":{"src":"https://rmkhnxnbeclogprvkfyl.supabase.co/storage/v1/object/public/firm-logos/312544/e851a3bf0ec2001e-r1.webp","tone":"light","width":791,"height":200,"sourceUrl":"https://paradigmbiocapital.com/","sourceLabel":"Paradigm Biocapital Advisors LP, website"},"classification":{"segment":"private_funds","segmentLabel":"Private funds","type":"private_fund_manager","typeLabel":null,"feeDisclosure":"payment_only"},"linkedinUrl":"https://www.linkedin.com/company/paradigm-biocapital","founded":null,"organization":"Delaware limited partnership","fiscalYearEnd":"December","headquarters":{"street":"520 Fifth Avenue, 23rd Floor","city":"New York","state":"NY","stateName":"New York","country":"United States","postalCode":"10036"},"tradeNames":[],"registration":{"secApproved":"23 February 2021","noticeFilings":null,"latestNoticeFiling":null},"wealthAumPerClient":null,"staff":{"employees":11,"advisory":6,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"regulatory":4469161523,"discretionary":4469161523,"discretionaryAccounts":4,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":50,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":3,"regulatoryAum":4004118132},{"label":"Other","clients":1,"fewerThan5":true,"regulatoryAum":465043391}],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[{"name":"Morgan Stanley & Co. LLC","shortName":"Morgan Stanley","location":"New York, NY","smaAssets":232804693},{"name":"J.P. Morgan Securities LLC","shortName":"J.P. Morgan","location":"New York, NY","smaAssets":123045624},{"name":"Merrill Lynch Professional Clearing Corp.","shortName":"Merrill Lynch Professional Clearing","location":"New York, NY","smaAssets":94892247}],"custodyNote":"Paradigm BioCapital Advisors has custody of $4B in client assets for 3 clients.","otherCustodians":[],"leadership":[{"name":"David Kim","title":"Chief Operating Officer / Chief Compliance Officer","crd":"5093183"},{"name":"DR. Senai Asefaw","title":"Chief Investment Officer / Limited Partner","crd":"7328980"}],"ownership":[{"label":"DR. Senai Asefaw","detail":"Chief investment officer / limited partner in the 75% or more ownership band and a control person, since December 2020. Also a managing member of Paradigm Biocapital Advisors GP LLC in the 75% or more band and a control person, since January 2022."}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":0,"privateResidences":0},"listedOfficeAddresses":1,"foreignOffices":[],"officesByState":[{"state":"New York","offices":1,"addresses":[{"street":"520 Fifth Avenue, 23rd Floor","city":"New York","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"646-970-2568","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[{"label":"Exchange-traded equity securities","percent":95},{"label":"Non-exchange-traded equity securities","percent":2},{"label":"Cash and cash equivalents","percent":3}],"privateFunds":2},"sources":{"adv1FilingDate":"27 August 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/312544/PDF/312544.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","updatedOn":"2026-10-21","holdingsUpdatedOn":"2026-10-21","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Paradigm BioCapital Advisors have?","answer":"Paradigm BioCapital Advisors has 4 clients and manages $4.47 billion for them, as of August 2026. They include 3 pooled investment vehicles and 1 other client.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 27 August 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Paradigm BioCapital Advisors offer?","answer":"Paradigm BioCapital Advisors provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Which custodians does Paradigm BioCapital Advisors use?","answer":"Paradigm BioCapital Advisors’ separately managed account assets are held at Morgan Stanley & Co. LLC (New York, NY), with $233M, J.P. Morgan Securities LLC (New York, NY), with $123M and Merrill Lynch Professional Clearing Corp. (New York, NY), with $94.9M. Only custodians holding at least a tenth of those assets are named.","source":"Form ADV Part 1A, Schedule D, Section 5.K.(3), filed 27 August 2026","sourceRef":{"doc":"adv1","section":"custodians"}},{"question":"How many financial advisors does Paradigm BioCapital Advisors have?","answer":"Paradigm BioCapital Advisors has 0 investment adviser representatives registered with state securities authorities, out of 11 employees, and 6 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What does Paradigm BioCapital Advisors invest in?","answer":"At the end of its last fiscal year, Paradigm BioCapital Advisors’ separately managed accounts held 95% exchange-traded equities, 3% cash and equivalents and 2% non-exchange-traded equities. It advises 2 private funds.","source":"Form ADV Part 1A, Items 5.K.(1) and 7.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Paradigm BioCapital Advisors?","answer":"Paradigm BioCapital Advisors’ direct owner is DR. Senai Asefaw (75% or more).","source":"Form ADV Part 1A, Schedules A and B, filed 27 August 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Paradigm BioCapital Advisors get paid?","answer":"Paradigm BioCapital Advisors is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How do I contact Paradigm BioCapital Advisors?","answer":"Paradigm BioCapital Advisors’ main office is at 520 Fifth Avenue, 23rd Floor, New York, NY 10036. Its phone number is 646-970-2568. Its website is paradigmbiocapital.com.","source":"Form ADV Part 1A, Item 1.F, filed 27 August 2026","sourceRef":{"doc":"adv1","section":"offices"}}],"holdings":{"url":"https://nivawealth.com/firms/paradigm-biocapital-advisors-312544/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-14","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1855655/000185565526000014/0001855655-26-000014-index.html","totalValue":5340558034,"positionCount":28,"top10Share":0.7521098342960165,"top10":[{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"COM","cusip":"76155X100","value":1191348571,"shares":6361323,"shareType":"SH","priorValue":647267117,"priorShares":6655703},{"issuer":"NUVALENT INC","titleOfClass":"COM","cusip":"670703107","value":731667476,"shares":5924433,"shareType":"SH","priorValue":545488161,"priorShares":5324433},{"issuer":"EDGEWISE THERAPEUTICS INC","titleOfClass":"COM","cusip":"28036F105","value":415053937,"shares":10215455,"shareType":"SH","priorValue":231998697,"priorShares":7365038},{"issuer":"GENMAB A/S","titleOfClass":"SPONSORED ADS","cusip":"372303206","value":360767109,"shares":13133131,"shareType":"SH","priorValue":213777040,"priorShares":7967836},{"issuer":"SPYRE THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"00773J202","value":340984271,"shares":3840778,"shareType":"SH","priorValue":98724497,"priorShares":1957266},{"issuer":"APOGEE THERAPEUTICS INC","titleOfClass":"COM","cusip":"03770N101","value":209233581,"shares":1576385,"shareType":"SH","priorValue":113481613,"priorShares":1348243},{"issuer":"ORUKA THERAPEUTICS INC","titleOfClass":"COM","cusip":"687604108","value":204094539,"shares":2144526,"shareType":"SH","priorValue":113811500,"priorShares":2320316},{"issuer":"TANGO THERAPEUTICS INC","titleOfClass":"COM","cusip":"87583X109","value":198736169,"shares":6357523,"shareType":"SH","priorValue":83882485,"priorShares":4009679},{"issuer":"BELITE BIO INC","titleOfClass":"SPONSORED ADS","cusip":"07782B104","value":189844565,"shares":1232877,"shareType":"SH","priorValue":177741161,"priorShares":1114784},{"issuer":"ERASCA INC","titleOfClass":"COM","cusip":"29479A108","value":174956000,"shares":9550000,"shareType":"SH","priorValue":168153918,"priorShares":10392702}],"positionsListed":28,"positions":[{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"COM","cusip":"76155X100","value":1191348571,"shares":6361323,"shareType":"SH","priorValue":647267117,"priorShares":6655703},{"issuer":"NUVALENT INC","titleOfClass":"COM","cusip":"670703107","value":731667476,"shares":5924433,"shareType":"SH","priorValue":545488161,"priorShares":5324433},{"issuer":"EDGEWISE THERAPEUTICS INC","titleOfClass":"COM","cusip":"28036F105","value":415053937,"shares":10215455,"shareType":"SH","priorValue":231998697,"priorShares":7365038},{"issuer":"GENMAB A/S","titleOfClass":"SPONSORED ADS","cusip":"372303206","value":360767109,"shares":13133131,"shareType":"SH","priorValue":213777040,"priorShares":7967836},{"issuer":"SPYRE THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"00773J202","value":340984271,"shares":3840778,"shareType":"SH","priorValue":98724497,"priorShares":1957266},{"issuer":"APOGEE THERAPEUTICS INC","titleOfClass":"COM","cusip":"03770N101","value":209233581,"shares":1576385,"shareType":"SH","priorValue":113481613,"priorShares":1348243},{"issuer":"ORUKA THERAPEUTICS INC","titleOfClass":"COM","cusip":"687604108","value":204094539,"shares":2144526,"shareType":"SH","priorValue":113811500,"priorShares":2320316},{"issuer":"TANGO THERAPEUTICS INC","titleOfClass":"COM","cusip":"87583X109","value":198736169,"shares":6357523,"shareType":"SH","priorValue":83882485,"priorShares":4009679},{"issuer":"BELITE BIO INC","titleOfClass":"SPONSORED ADS","cusip":"07782B104","value":189844565,"shares":1232877,"shareType":"SH","priorValue":177741161,"priorShares":1114784},{"issuer":"ERASCA INC","titleOfClass":"COM","cusip":"29479A108","value":174956000,"shares":9550000,"shareType":"SH","priorValue":168153918,"priorShares":10392702},{"issuer":"TARSUS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"87650L103","value":174699348,"shares":2775649,"shareType":"SH","priorValue":179735103,"priorShares":2562154},{"issuer":"ALNYLAM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"02043Q107","value":144494400,"shares":480000,"shareType":"SH"},{"issuer":"INSMED INC","titleOfClass":"COM PAR $.01","cusip":"457669307","value":141375668,"shares":1325977,"shareType":"SH","priorValue":205133878,"priorShares":1254488},{"issuer":"MBX BIOSCIENCES INC","titleOfClass":"COM","cusip":"55287L101","value":138442428,"shares":2508015,"shareType":"SH"},{"issuer":"VAXCYTE INC","titleOfClass":"COM","cusip":"92243G108","value":123692037,"shares":2127852,"shareType":"SH","priorValue":278522392,"priorShares":4793020},{"issuer":"VIRIDIAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"92790C104","value":123515986,"shares":6723788,"shareType":"SH","priorValue":61592347,"priorShares":3148893},{"issuer":"OLEMA PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"68062P106","value":108468906,"shares":8670576,"shareType":"SH","priorValue":119586788,"priorShares":8020576},{"issuer":"JADE BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"008064206","value":63491539,"shares":2857405,"shareType":"SH"},{"issuer":"TYRA BIOSCIENCES INC","titleOfClass":"COM","cusip":"90240B106","value":58405708,"shares":1828607,"shareType":"SH","priorValue":78706155,"priorShares":2054991},{"issuer":"ASSEMBLY BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"045396207","value":42696995,"shares":1553748,"shareType":"SH","priorValue":18460715,"priorShares":665251},{"issuer":"EYEPOINT INC","titleOfClass":"COM NEW","cusip":"30233G209","value":41332677,"shares":2890397,"shareType":"SH","priorValue":40506013,"priorShares":3142437},{"issuer":"ACHIEVE LIFE SCIENCE INC","titleOfClass":"COM","cusip":"004468500","value":32335620,"shares":4951856,"shareType":"SH"},{"issuer":"VOR BIOPHARMA INC","titleOfClass":"COM NEW","cusip":"929033207","value":32217500,"shares":1750000,"shareType":"SH","priorValue":31220000,"priorShares":1750000},{"issuer":"MAPLIGHT THERAPEUTICS INC","titleOfClass":"COM","cusip":"56565P103","value":24580936,"shares":685852,"shareType":"SH"},{"issuer":"KARDIGAN INC","titleOfClass":"COM","cusip":"485925101","value":21465000,"shares":900000,"shareType":"SH"},{"issuer":"LEXEO THERAPEUTICS INC","titleOfClass":"COM","cusip":"52886X107","value":19436403,"shares":4175382,"shareType":"SH","priorValue":35496929,"priorShares":6184134},{"issuer":"EDITAS MEDICINE INC","titleOfClass":"COM","cusip":"28106W103","value":18100665,"shares":5586625,"shareType":"SH"},{"issuer":"INVENTIVA SA","titleOfClass":"ADS","cusip":"46124U107","value":15120000,"shares":4000000,"shareType":"SH","priorValue":22200000,"priorShares":4000000}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}